Daxor Co. (NASDAQ:DXR) Short Interest Up 7.1% in December

Daxor Co. (NASDAQ:DXR) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 15th total of 8,400 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.5% of the shares of the company are short sold.

Daxor Price Performance

Shares of Daxor stock opened at $8.50 on Tuesday. Daxor has a 1 year low of $7.19 and a 1 year high of $10.02. The company’s fifty day moving average is $8.55 and its two-hundred day moving average is $8.80.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its position in Daxor Co. (NASDAQ:DXR) by 34.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,612 shares of the company’s stock after buying an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent SEC filing. Institutional investors own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.